BMY to re-submit Vanlev NDA

Bristol-Myers Squibb (BMY) plans to re-submit by year end an NDA to the FDA for its Vanlev omapatrilat, a vasopeptidase inhibitor, to treat hypertension. Last year, BMY withdrew the NDA in response to...